PDF icon Download PDF
Open Access
CC BY-NC-ND 4.0 · South Asian J Cancer 2018; 07(02): 102-105
DOI: 10.4103/sajc.sajc_111_18
Original Article

Practical consensus recommendations regarding the management of HER2 neu positive early breast cancer

A. Bahl
Deparment of Medical Oncology, Max Hospital, New Delhi
,
R. Singh
Department of Medical Oncology, Artemis Hospital, Gurugram
,
J. Wadhwa
Department of Medical Oncology, Medanta Hospital, Gurugram
,
S. Gupta
Department of Medical Oncology, Sarvodaya Hospital, New Delhi
,
M. Ahmed
Departmentt of Radiation Oncology, Jolly Grant Himalayan Institute, Dehradoon
,
P. N. Uppal
Department of Surgical Oncology, Jaipur Golden Hospital, New Delhi
,
Purvish M. Parikh
Department of Oncology, Shalby Cancer and Research Institute, Mumbai, Maharashtra
,
S. Aggarwal
Department of Medical Oncology, Sir Ganga Ram Hospital, New Delhi
› Author Affiliations
Financial support and sponsorship: Nil.
› Further Information
Also available ateRef
 PDF Download Permissions and Reprints
Preview

Abstract

Over-expression of HER2 is generally considered to be a negative prognostic feature because it accompanies an increase in breast cancer mortality. However, the development of agents that specifically target HER2 has improved the management of patients with these tumours. This expert group used data from published literature, practical experience and opinion of a large group of academic oncologists to arrive at these practical consensus recommendations with regards to the use of these agents and the management of HER2 neu early breast cancer for the benefit of community oncologists.

Key words

Adjuvant trastuzumab - double agent - TCH regimen - tumor size


Publication History

Article published online:
22 December 2020

© 2018. MedIntel Services Pvt Ltd. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/.)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Vaidyanathan K, Kumar P, Reddy CO, Deshmane V, Somasundaram K, Mukherjee G, et al. ErbB-2 expression and its association with other biological parameters of breast cancer among Indian women. Indian J Cancer 2010;47:8-15.
  • 2 Nikhra P, Patel S, Taviad D, Chaudhary S. Study of ER (Estrogen Receptor), PR (Progesterone Receptor) and HER-2/NEU (Human Epidermal Growth Factor Receptor) expression by immunohistochemistry in breast carcinoma. Int J Biomed Adv Res 2014;5:275-8.
  • 3 Zubeda S, Kaipa PR, Shaik NA, Mohiuddin MK, Vaidya S, Pavani B, et al. Her-2/neu status: A neglected marker of prognostication and management of breast cancer patients in India. Asian Pac J Cancer Prev 2013;14:2231-5.
  • 4 Dykins R, Corbett IP, Henry JA, Wright C, Yuan J, Hennessy C, et al. Long-term survival in breast cancer related to overexpression of the c-erbB-2 oncoprotein: An immunohistochemical study using monoclonal antibody NCL-CB11. J Pathol 1991;163:105-10.
  • 5 Andrulis IL, Bull SB, Blackstein ME, Sutherland D, Mak C, Sidlofsky S, et al. Neu/erbB-2 amplification identifies a poor-prognosis group of women with node-negative breast cancer. Toronto Breast Cancer Study Group. J Clin Oncol 1998;16:1340-9.
  • 6 Hartmann LC, Ingle JN, Wold LE, Farr GH Jr., Grill JP, Su JQ, et al. Prognostic value of c-erbB2 overexpression in axillary lymph node positive breast cancer. Results from a randomized adjuvant treatment protocol. Cancer 1994;74:2956-63.
  • 7 Press MF, Pike MC, Chazin VR, Hung G, Udove JA, Markowicz M, et al. Her-2/neu expression in node-negative breast cancer: Direct tissue quantitation by computerized image analysis and association of overexpression with increased risk of recurrent disease. Cancer Res 1993;53:4960-70.
  • 8 Seshadri R, Firgaira FA, Horsfall DJ, McCaul K, Setlur V, Kitchen P, et al. Clinical significance of HER-2/neu oncogene amplification in primary breast cancer. The South Australian Breast Cancer Study Group. J Clin Oncol 1993;11:1936-42.
  • 9 Têtu B, Brisson J. Prognostic significance of HER-2/neu oncoprotein expression in node-positive breast cancer. The influence of the pattern of immunostaining and adjuvant therapy. Cancer 1994;73:2359-65.
  • 10 Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE Jr. Davidson NE, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005;353:1673-84.
  • 11 Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005;353:1659-72.
  • 12 Slamon D, Eiermann W, Robert N. Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (ACT) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (ACTH) with docetaxel, carboplatin and trastuzumab (TCH) in HER2 positive early breast cancer patients: BCIRG 006 study. Breast Cancer Res Treat 2005;94 Suppl 1:S5a.
  • 13 Joensuu H, Kellokumpu-Lehtinen PL, Bono P, Alanko T, Kataja V, Asola R, et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 2006;354:809-20.
  • 14 Ghosh J, Gupta S, Desai S, Shet T, Radhakrishnan S, Suryavanshi P, et al. Estrogen, progesterone and HER2 receptor expression in breast tumors of patients, and their usage of HER2-targeted therapy, in a tertiary care centre in India. Indian J Cancer 2011;48:391-6.
  • 15 Adusumilli P, Konatam ML, Gundeti S, Bala S, Maddali LS. Treatment challenges and survival analysis of human epidermal growth factor receptor 2-positive breast cancer in real world. Indian J Med Paediatr Oncol 2017;38:22-7.
  • 16 Fehrenbacher L, Capra AM, Quesenberry CP Jr., Fulton R, Shiraz P, Habel LA, et al. Distant invasive breast cancer recurrence risk in human epidermal growth factor receptor 2-positive T1a and T1b node-negative localized breast cancer diagnosed from 2000 to 2006: A cohort from an integrated health care delivery system. J Clin Oncol 2014;32:2151-8.
  • 17 Rocque G, Onitilo A, Engel J, Pettke E, Boshoven A, Kim K, et al. Adjuvant therapy for HER2+breast cancer: Practice, perception, and toxicity. Breast Cancer Res Treat 2012;131:713-21.
  • 18 Gonzalez-Angulo AM, Litton JK, Broglio KR, Meric-Bernstam F, Rakkhit R, Cardoso F, et al. High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller. J Clin Oncol 2009;27:5700-6.
  • 19 Curigliano G, Viale G, Bagnardi V, Fumagalli L, Locatelli M, Rotmensz N, et al. Clinical relevance of HER2 overexpression/amplification in patients with small tumor size and node-negative breast cancer. J Clin Oncol 2009;27:5693-9.
  • 20 Zhou Q, Yin W, Du Y, Lu J. For or against adjuvant trastuzumab for pT1a-bN0M0 breast cancer patients with HER2-positive tumors: A meta-analysis of published literatures. PLoS One 2014;9:e83646.
  • 21 Rodrigues MJ, Wassermann J, Albiges L, Brain E, Delaloge S, Stevens D, et al. Trastuzumab treatment in t1ab, node-negative, human epidermal growth factor receptor 2-overexpressing breast carcinomas. J Clin Oncol 2010;28:e541-2.
  • 22 McArthur HL, Patil S. Benefits of Trastuzumab-Based Therapy for Women with Small, Node-Negative, HER2-Positive Breast Cancer. San Francisco, CA: ASCO Breast Cancer Symposium; 2009.
  • 23 van Ramshorst MS, van der Heiden-van der Loo M, Dackus GM, Linn SC, Sonke GS. The effect of trastuzumab-based chemotherapy in small node-negative HER2-positive breast cancer. Breast Cancer Res Treat 2016;158:361-71.
  • 24 Moja L, Tagliabue L, Balduzzi S, Parmelli E, Pistotti V, Guarneri V, et al. Efficacy and safety of trastuzumab in early breast cancer. Cochrane Rev 2012.
  • 25 National Comprehensive Cancer Network. Available from: http://www.nccn.org. [Last accessed on 2017 Nov 21].
  • 26 Slamon D, Eiermann W, Robert N, Pienkowski T, Martin M, Press M, et al. Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med 2011;365:1273-83.
  • 27 Swain SM, Whaley FS, Ewer MS. Congestive heart failure in patients treated with doxorubicin: A retrospective analysis of three trials. Cancer 2003;97:2869-79.
  • 28 Valcovici M, Andrica F, Serban C, Dragan S. Cardiotoxicity of anthracycline therapy: Current perspectives. Arch Med Sci 2016;12:428-35.
  • 29 McGowan JV, Chung R, Maulik A, Piotrowska I, Walker JM, Yellon DM, et al. Anthracycline chemotherapy and cardiotoxicity. Cardiovasc Drugs Ther 2017;31:63-75.
  • 30 Tolaney SM, Barry WT, Dang CT, Yardley DA, Moy B, Marcom PK, et al. Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer. N Engl J Med 2015;372:134-41.
  • 31 Hayes DF, Thor AD, Dressler LG, Weaver D, Edgerton S, Cowan D, et al. HER2 and response to paclitaxel in node-positive breast cancer. N Engl J Med 2007;357:1496-506.
  • 32 Piccart-Gebhart M, Holmes E, Baselga J, de Azambuja E, Dueck AC, Viale G, et al. Adjuvant lapatinib and trastuzumab for early human epidermal growth factor receptor 2-positive breast cancer: Results from the randomized phase III adjuvant lapatinib and/or trastuzumab treatment optimization trial. J Clin Oncol 2016;34:1034-42.
  • 33 Dang C, Lin N, Moy B, Come S, Sugarman S, Morris P, et al. Dose-dense doxorubicin and cyclophosphamide followed by weekly paclitaxel with trastuzumab and lapatinib in HER2/neu-overexpressed/amplified breast cancer is not feasible because of excessive diarrhea. J Clin Oncol 2010;28:2982-8.
  • 34 Moreno-Aspitia A, Dueck AC, Ghanem-Cañete I, Patel T, Dakhil S, Johnson D, et al. RC0639: Phase II study of paclitaxel, trastuzumab, and lapatinib as adjuvant therapy for early stage HER2-positive breast cancer. Breast Cancer Res Treat 2013;138:427-35.
  • 35 Weiss RB. The anthracyclines: Will we ever find a better doxorubicin? Semin Oncol 1992;19:670-86.
  • 36 Minotti G, Menna P, Salvatorelli E, Cairo G, Gianni L. Anthracyclines: Molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev 2004;56:185-229.
  • 37 Peng X, Chen B, Lim CC, Sawyer DB. The cardiotoxicology of anthracycline chemotherapeutics: Translating molecular mechanism into preventative medicine. Mol Interv 2005;5:163-71.
  • 38 Lyman GH, Kuderer NM, Crawford J, Wolff DA, Culakova E, Poniewierski MS, et al. Predicting individual risk of neutropenic complications in patients receiving cancer chemotherapy. Cancer 2011;117:1917-27.
  • 39 Jones SE, Savin MA, Holmes FA, O'Shaughnessy JA, Blum JL, Vukelja S, et al. Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer. J Clin Oncol 2006;24:5381-7.
  • 40 Tuma R. Anthracycline therapy may be avoidable in early breast cancer, new studies suggest. J Natl Cancer Inst 2008;100:459-61.
  • 41 Slamon DL, Swain SM, Buyse M. Primary results from BETH, a phase 3 controlled study of adjuvant chemotherapy and trastuzumab±bevacizumab in patients with HER2-positive, node-positive, or high-risk node-negative breast cancer. San Antonio Breast Cancer Symposium; 2013.
  • 42 Savage L, Andrea Widener A. Anthracyclines improve survival in HER2-positive breast cancer patients. J Natl Cancer Inst 2008;100:1.
  • 43 Muss HB, Thor AD, Berry DA, Kute T, Liu ET, Koerner F, et al. C-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. N Engl J Med 1994;330:1260-6.
  • 44 Gennari A, Sormani MP, Pronzato P, Puntoni M, Colozza M, Pfeffer U, et al. HER2 status and efficacy of adjuvant anthracyclines in early breast cancer: A pooled analysis of randomized trials. J Natl Cancer Inst 2008;100:14-20.
  • 45 Dhesy-Thind B, Pritchard KI, Messersmith H, O'Malley F, Elavathil L, Trudeau M, et al. HER2/neu in systemic therapy for women with breast cancer: A systematic review. Breast Cancer Res Treat 2008;109:209-29.
  • 46 Pritchard KI, Messersmith H, Elavathil L, Trudeau M, O'Malley F, Dhesy-Thind B, et al. HER-2 and topoisomerase II as predictors of response to chemotherapy. J Clin Oncol 2008;26:736-44.